Abstract
Copper-67 (67Cu) is one of the most compromising radiometals for radioimmunotherapy because of its 61.5 hr physical half-life, abundant beta particles, and gamma emmissions suitable for imaging. However, 67Cu is readily tranferred from the usual chelates of EDTA or DTPA to albumen. We developed a new macrocycle (6-p-nitrobenzyl-TETA) to chelate copper. Bifunctional chelating agent p-bromoacetamidobenzyl-TETA was conjugated to Lym-1, a monoclonal antibody against human B cell lymphoma, without significantly altering its immunoreactivity. This conjugate was stably labeled with 67Cu under conditions chosen to optimize the yield of a high specific activity radiopharmaceutical. The biodistribution in RAJI tumor bearing mice demonstrated significant tumor uptake (14.7% ID per gram) and extended residence time (120 hr) in contrast to normal organs. After 24 hr, radioactivity was continuously cleared from all tissues except the tumor. This study suggests 67Cu labeled Lym-1 to be a promising radiopharmaceutical for potential use for radioimmunotherapy of B cell lymphoma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 217-225 |
| Number of pages | 9 |
| Journal | Journal of Nuclear Medicine |
| Volume | 29 |
| Issue number | 2 |
| State | Published - 1988 |
Fingerprint
ASJC Scopus subject areas
- Radiological and Ultrasound Technology
Cite this
Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy : Labeling and biodistribution in RAJI tumored mice. / Desphande, S. V.; DeNardo, S. J.; Meares, C. F.; McCall, M. J.; Adams, G. P.; Moi, M. K.; Denardo, Gerald L.
In: Journal of Nuclear Medicine, Vol. 29, No. 2, 1988, p. 217-225.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy
T2 - Labeling and biodistribution in RAJI tumored mice
AU - Desphande, S. V.
AU - DeNardo, S. J.
AU - Meares, C. F.
AU - McCall, M. J.
AU - Adams, G. P.
AU - Moi, M. K.
AU - Denardo, Gerald L
PY - 1988
Y1 - 1988
N2 - Copper-67 (67Cu) is one of the most compromising radiometals for radioimmunotherapy because of its 61.5 hr physical half-life, abundant beta particles, and gamma emmissions suitable for imaging. However, 67Cu is readily tranferred from the usual chelates of EDTA or DTPA to albumen. We developed a new macrocycle (6-p-nitrobenzyl-TETA) to chelate copper. Bifunctional chelating agent p-bromoacetamidobenzyl-TETA was conjugated to Lym-1, a monoclonal antibody against human B cell lymphoma, without significantly altering its immunoreactivity. This conjugate was stably labeled with 67Cu under conditions chosen to optimize the yield of a high specific activity radiopharmaceutical. The biodistribution in RAJI tumor bearing mice demonstrated significant tumor uptake (14.7% ID per gram) and extended residence time (120 hr) in contrast to normal organs. After 24 hr, radioactivity was continuously cleared from all tissues except the tumor. This study suggests 67Cu labeled Lym-1 to be a promising radiopharmaceutical for potential use for radioimmunotherapy of B cell lymphoma.
AB - Copper-67 (67Cu) is one of the most compromising radiometals for radioimmunotherapy because of its 61.5 hr physical half-life, abundant beta particles, and gamma emmissions suitable for imaging. However, 67Cu is readily tranferred from the usual chelates of EDTA or DTPA to albumen. We developed a new macrocycle (6-p-nitrobenzyl-TETA) to chelate copper. Bifunctional chelating agent p-bromoacetamidobenzyl-TETA was conjugated to Lym-1, a monoclonal antibody against human B cell lymphoma, without significantly altering its immunoreactivity. This conjugate was stably labeled with 67Cu under conditions chosen to optimize the yield of a high specific activity radiopharmaceutical. The biodistribution in RAJI tumor bearing mice demonstrated significant tumor uptake (14.7% ID per gram) and extended residence time (120 hr) in contrast to normal organs. After 24 hr, radioactivity was continuously cleared from all tissues except the tumor. This study suggests 67Cu labeled Lym-1 to be a promising radiopharmaceutical for potential use for radioimmunotherapy of B cell lymphoma.
UR - http://www.scopus.com/inward/record.url?scp=0023832349&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023832349&partnerID=8YFLogxK
M3 - Article
C2 - 3258025
AN - SCOPUS:0023832349
VL - 29
SP - 217
EP - 225
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
SN - 0161-5505
IS - 2
ER -